J Neurocrit Care.  2017 Dec;10(2):76-85. 10.18700/jnc.170032.

Corticosteroids Treatment in Spinal Cord and Neuromuscular Disorders

• Na SJ

• KMID: 2405761
• DOI: http://doi.org/10.18700/jnc.170032

Abstract

Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of the vertebrates, as well as the synthetic analogs of these hormones that are synthesized in the laboratories. Two main classes of corticosteroids, glucocorticoids, and mineralocorticoids, are involved in a wide range of physiologic processes, including stress response, immune response, and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior. Corticosteroids have been used for almost 60 years in medicine and their roles in patients have always been discussed by researchers and clinicians dedicated in the related field. Currently, they are still used in the treatment of patients with neurological disorders. Usually, corticosteroids are used in the treatment of various inflammatory diseases and conditions. In this review, we present five key indications, i.e., neuromyelitis optica, acute spinal cord injury, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, polymyositis/dermatomyositis for the systemic use of corticosteroids in neurology based on a mix of quality of evidence, prevalence, and impact on disease management.

Keyword

Corticosteroids; Neuromyelitis optica; Acute spinal cord injury; Chronic inflammatory demyelinating polyneuropathy; Myasthenia gravis; Polymyositis/dermatomyositis

MeSH Terms

Adrenal Cortex
Adrenal Cortex Hormones*
Carbohydrate Metabolism
Disease Management
Glucocorticoids
Humans
Inflammation
Metabolism
Mineralocorticoids
Myasthenia Gravis
Nervous System Diseases
Neurology
Neuromyelitis Optica
Polyneuropathies
Prevalence
Spinal Cord Injuries
Spinal Cord*
Vertebrates
Adrenal Cortex Hormones
Glucocorticoids
Mineralocorticoids

Reference

1. Nussey S, Whitehead S. Enocrinology: An Intergrated Approch. 1th ed. Oxford: BIOS Scientific Publishers;2001. p. 115–68.

2. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013; 9:30.

3. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53:1107–14.

4. Biswas A, Mukherjee A. Therapy of NMO spectrum disorders. Ann Indian Acad Neurol. 2015; 18(Suppl 1):S16–23.

5. Bracken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA. 1984; 251:45–52.

6. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinalcord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990; 322:1405–11.

7. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA. 1997; 277:1597–604.

8. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev. 2012; 1:CD001046.

9. Ahuja CS, Nori S, Tetreault L, Wilson J, Kwon B, Harrop J, et al. Traumatic spinal cord injury-repair and regeneration. Neurosurgery. 2017; 80(3S):S9–22.

10. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain. 1987; 110(Pt 6):1617–30.

11. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989; 46:878–84.

12. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology. 1993; 43:2202–9.

13. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997; 48:321–8.

14. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975; 50:621–37.

15. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982; 11:136–41.

16. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2002; (1):CD002062.

17. Brannagan TH 3rd. Current treatments of chronic immunemediated demyelinating polyneuropathies. Muscle Nerve. 2009; 39:563–78.

18. Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol. 2005; 62:249–54.

19. Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol. 2008; 65:1460–4.

20. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2004; (4):CD003280.

21. Simmons Z. Treatment and Management of Autoimmune Neuropathies. In : Bertorini TE, editor. Neuromuscular Disorders: Treatment and Management. 1st ed. Philadelphia: Saunders;2011. p. 215–35.

22. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010; 9:245–53.

23. Dalakas MC; Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011; 7:507–17.

24. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004; 50:3408–17.

25. Gorson KC, van Schaik IN, Merkies IS, Lewis RA, Barohn RJ, Koski CL, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst. 2010; 15:326–33.

26. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN; PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology. 2012; 78:1079–84.

27. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012; 11:493–502.

28. Börü ÜT, Erdoğan H, Alp R, Taşdemir M, Yıldırım S, Bilgiç A, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-year follow up. Clin Neurol Neurosurg. 2014; 118:89–93.

29. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol. 2008; 4:317–27.

30. Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998; 97:370–3.

31. Howard FM Jr, Duane DD, Lambert EH, Daube JR. Alternateday prednisone: preliminary report of a double-blind controlled study. Ann N Y Acad Sci. 1976; 274:596–607.

32. Schuchardt V, Kohler W, Hund E, Scheglmann K, Fleisher E, Jung K, et al. A randomized, controlled trial of high-dose intravenous immunoglobulin versus methylprednisolone in moderate exacerbations of myasthenia gravis: final analysis after early termination (unpublished data). Cited in Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR: Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2015; (2):CD002828.

33. Millikan CH, Eaton LM. Clinical-evaluation of ACTH and cortisone in myasthenia gravis. Neurology. 1951; 1:145–52.

34. Grob D, Harvey AM. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. Bull Johns Hopkins Hosp. 1952; 91:124–36.

35. Bae JS, Go SM, Kim BJ. Clinical predictors of steroid induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006; 13:1006–10.

36. Abramsky O, Aharonov A, Teitelbaum D, Fuchs S. Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch Neurol. 1975; 32:684–7.

37. Cohen IR, Stavy L, Feldman M. Glucocorticoids and cellular immunity in vitro. Facilitation of the sensitization phase and inhibition of the effector phase of a lymphocyte anti-fibroblast reaction. J Exp Med. 1970; 132:1055–70.

38. Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med. 1974; 290:81–4.

39. Drachman DB. Myasthenia gravis. N Engl J Med. 1994; 330:1797–810.

40. Durelli L, Maggi G, Casadio C, Ferri R, Rendine S, Bergamini L. Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients. J Neurol Neurosurg Psychiatry. 1991; 54:406–11.

41. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010; 17:893–902.

42. Miano MA, Bosley TM, Heiman-Patterson TD, Reed J, Sergott RC, Savino PJ, et al. Factors influencing outcome of prednisone dose reduction in myasthenia gravis. Neurology. 1991; 41:919–21.

43. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008; 71:394–9.

44. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, phase III, randomized trial of mycophenolate mycophenolate mofetil in myasthenia gravis. Neurology. 2008; 71:400–6.

45. Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011; 82:970–7.

46. Benatar M, Kaminski HJ; Quality Standards Subcommittee of the American Academy of Neurology. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2007; 68:2144–9.

47. Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand. 1988; 77:31–5.

48. Mount FW. Corticotropin in treatment of ocular myasthenia; a controlled clinical trial. Arch Neurol. 1964; 11:114–24.

49. Fisher KC, Schwartzman RJ. Oral corticosteroids in the treatment of ocular myasthenia gravis. Ann N Y Acad Sci. 1976; 274:652–8.

50. Nakamura H, Taniguchi Y, Suzuki Y, Tanaka Y, Ishiguro K, Fukuda M, et al. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. J Thorac Cardiovasc Surg. 1996; 112:371–5.

51. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997; 62:156–62.

52. Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology. 2008; 71:1335–41.

53. Bruce BB, Kupersmith MJ. Safety of prednisone for ocular myasthenia gravis. J Neuroophthalmol. 2012; 32:212–5.

54. Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol. 1996; 53:802–4.

55. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003; 60:243–8.

56. Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003; 23:251–5.

57. Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve. 2010; 41:379–84.

58. Agius MA. Treatment of ocular myasthenia with corticosteroids: yes. Arch Neurol. 2000; 57:750–1.

59. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord. 2001; 11:208–16.

60. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993; 94:379–87.

61. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nature Review Rheumatol. 2010; 6:129–37.

62. Dalakas MC. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol. 2003; 23:199–206.

63. Hohlfeld R, Dalakas MC. Basic principles of immunotherapy for neurologic diseases. Semin Neurol. 2003; 23:121–32.

64. Mastaglia FL, Phillips BA, Zilko P. Treatment of inflammatory myopathies. Muscle Nerve. 1997; 20:651–64.

65. Mastaglia FL. Treatment of autoimmune inflammatory myopathies. Curr Opin Neurol. 2000; 13:507–9.

66. Dalakas MC. Therapy for immune-mediated inflammatory myopathies. In : Johnson RT, Griffin JW, McArthur JC, editors. 7th ed. 7. Philadelphia: Mosby;2006. p. 396–402.

67. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. In : Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. 15th ed. New York: McGraw-Hill;2001. p. 2524–9.

68. Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis/ dermatomyositis. Adv Exp Med Biol. 1999; 455:349–57.

69. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005; 84:231–49.

70. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effects of a hormone of the adrenal cortex (17-hydroxy-11-dehydorcorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949; 24:181–97.

71. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic). 1950; 85:545–666.

72. Polley HF. Present therapeutic status of cortisone and its derivatives, with special reference to rheumatic diseases. Br Med J. 1956; 2:1253–9.

73. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990; 19:126–46.

74. Schimmer BP, Funder JW. ACTH, Adrenal Steroids, and Pharmacology of the Adrenal Cortex. In : Brunton L, Chabner BA, Knollman B, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill Education;2011. p. 1209–36.